Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C972
http://purl.obolibrary.org/obo/NCIT_C972
|
|---|---|
| Preferred Name | Esorubicin |
| Definitions |
A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class. |
|---|---|
| label | Esorubicin
|
| prefLabel | Esorubicin
|
| Legacy Concept Name | Deoxydoxorubicin
|
| in_subset | |
| Preferred_Name | Esorubicin
|
| Is_Value_For_GDC_Property | |
| Chemical_Formula | C27H29NO10
|
| Maps_To | Esorubicin
|
| PDQ_Open_Trial_Search_ID | 39211
|
| UMLS_CUI | C0047760
|
| FDA_UNII_Code | RMC41L2WQ3
|
| prefixIRI | NCIT:C972
|
| NCI_Drug_Dictionary_ID | 39211
|
| Contributing_Source | FDA
|
| subClassOf | |
| Has_Salt_Form | |
| code | C972
|
| type | |
| NSC Number | 267469
|
| PDQ_Closed_Trial_Search_ID | 39211
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
Antibiotic
|
| CAS_Registry | 63521-85-7
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |